4
Changes in Ownership
GeneDx Holdings Corp. Filed Acc 0001689575-26-000021
CHIEF EXECUTIVE OFFICER sold 46,933 shares at an average $63.17 ($2,964,841)
- CHIEF EXECUTIVE OFFICER acquired 80,000 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Stueland Katherine CHIEF EXECUTIVE OFFICER | 2026-03-26 | Option exercise | +80,000 | 138,447 | D | ||
| Stueland Katherine CHIEF EXECUTIVE OFFICER | 2026-03-26 | Sale | −13,229 | $61.29 | $810,817 | 125,218 | D |
| Stueland Katherine CHIEF EXECUTIVE OFFICER | 2026-03-26 | Sale | −5,117 | $62.33 | $318,952 | 120,101 | D |
| Stueland Katherine CHIEF EXECUTIVE OFFICER | 2026-03-26 | Sale | −13,412 | $63.28 | $848,699 | 106,689 | D |
| Stueland Katherine CHIEF EXECUTIVE OFFICER | 2026-03-26 | Sale | −5,292 | $64.60 | $341,859 | 101,397 | D |
| Stueland Katherine CHIEF EXECUTIVE OFFICER | 2026-03-26 | Sale | −9,883 | $65.21 | $644,513 | 91,514 | D |
| Derivatives | |||||||
| Stueland Katherine CHIEF EXECUTIVE OFFICER | 2026-03-26 | Option exercise · Restricted Stock Unit | −80,000 | 160,000 | D | ||
| Open-market sales · 46,933 sh · avg $63.17 · $2,964,841 | |||||||
Loading xslF345X06/form4-03302026_080325.xml…